Clovis Oncology (NASDAQ:CLVS) was up 4.5% during trading on Monday . The company traded as high as $10.25 and last traded at $10.04, approximately 9,156,723 shares were traded during mid-day trading. A decline of 48% from the average daily volume of 17,555,998 shares. The stock had previously closed at $9.61.
Several research firms have weighed in on CLVS. Bank of America set a $7.00 price target on Clovis Oncology and gave the stock a “hold” rating in a research note on Friday, September 27th. HC Wainwright set a $36.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a research report on Monday, September 30th. Svb Leerink downgraded shares of Clovis Oncology from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $22.00 to $10.00 in a report on Tuesday, September 24th. Leerink Swann lowered shares of Clovis Oncology from an “outperform” rating to a “market perform” rating and set a $10.00 target price for the company. in a research report on Tuesday, September 24th. Finally, ValuEngine cut shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $19.92.
The business’s fifty day moving average is $6.72 and its two-hundred day moving average is $8.84. The company has a quick ratio of 3.53, a current ratio of 3.76 and a debt-to-equity ratio of 8.04. The stock has a market capitalization of $526.77 million, a PE ratio of -1.47 and a beta of 3.12.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.89) by $0.17. Clovis Oncology had a negative net margin of 298.53% and a negative return on equity of 1,576.32%. The company had revenue of $37.60 million for the quarter, compared to the consensus estimate of $35.84 million. During the same quarter in the prior year, the firm earned ($1.71) earnings per share. Clovis Oncology’s revenue was up 65.2% on a year-over-year basis. Sell-side analysts expect that Clovis Oncology will post -7.35 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. First Trust Advisors LP bought a new position in shares of Clovis Oncology in the 2nd quarter valued at about $723,000. Gabelli Funds LLC raised its position in Clovis Oncology by 36.3% during the third quarter. Gabelli Funds LLC now owns 148,400 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 39,500 shares during the period. Moloney Securities Asset Management LLC bought a new stake in shares of Clovis Oncology in the 3rd quarter valued at approximately $236,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Clovis Oncology by 3.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 301,445 shares of the biopharmaceutical company’s stock worth $4,483,000 after purchasing an additional 10,217 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Clovis Oncology by 13.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 39,047 shares of the biopharmaceutical company’s stock worth $581,000 after purchasing an additional 4,571 shares during the period. Hedge funds and other institutional investors own 92.21% of the company’s stock.
About Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Story: Why is the conference call important?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.